DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Antineoplaston A10 is an investigational drug.
There have been 55 clinical trials for Antineoplaston A10. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2018.
The most common disease conditions in clinical trials are Nervous System Neoplasms, Central Nervous System Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Burzynski Research Institute and [disabled in preview].
There are two hundred and thirty-eight US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Antineoplaston A10
|Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma||Burzynski Research Institute||Phase 3|
|Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma||Burzynski Research Institute||Phase 3|
|Antineoplaston Therapy in Treating Patients With Glioblastoma Multiforme||Burzynski Research Institute||Phase 2|
Top disease conditions for Antineoplaston A10
Top clinical trial sponsors for Antineoplaston A10
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Antineoplaston A10||Get Started Free||Synergistic compositions for treating microbial infections||University of Rochester (Rochester, NY) Temple University--Of the Commonwealth System of Higher Education (Philadelphia, PA)||Get Started Free|
|Antineoplaston A10||Get Started Free||Combination methods for treating cancers||Gilead Sciences, Inc. (Foster City, CA)||Get Started Free|
|Antineoplaston A10||Get Started Free||Phosphatidylinositol 3-kinase inhibitors||Gilead Sciences, Inc. (Foster City, CA)||Get Started Free|
|Antineoplaston A10||Get Started Free||Crystalline forms of tyrosine kinase inhibitors and their salts||Purdue Pharma, L.P. (Stamford, CT)||Get Started Free|
|Antineoplaston A10||Get Started Free||Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders||CASE WESTERN RESERVE UNIVERSITY (Cleveland, OH)||Get Started Free|
|Antineoplaston A10||Get Started Free||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||Get Started Free|
|Antineoplaston A10||Get Started Free||Multi-component nanochains||Case Western Reserve University (Cleveland, OH)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Antineoplaston A10||Australia||AU2015339039||2034-10-31||Get Started Free|
|Antineoplaston A10||Canada||CA2965839||2034-10-31||Get Started Free|
|Antineoplaston A10||China||CN107106533||2034-10-31||Get Started Free|
|Antineoplaston A10||European Patent Office||EP3212183||2034-10-31||Get Started Free|
|Antineoplaston A10||Japan||JP2017538675||2034-10-31||Get Started Free|
|Antineoplaston A10||Japan||JP6590924||2034-10-31||Get Started Free|
|Antineoplaston A10||World Intellectual Property Organization (WIPO)||WO2016070021||2034-10-31||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|